Search
forLearn
5 / 801 resultslearn Beclomethasone
learn Prednisolone
learn TRIOXIDIL®
learn Betamethasone
Research
5 / 1000+ results
research Realising the therapeutic potential of neuroactive steroid modulators of the GABAA receptor
Neuroactive steroids show promise for treating mental and neurological disorders by targeting GABA_A receptors.
research Relating neurosteroid modulation of inhibitory neurotransmission to behaviour
Neurosteroids can influence behavior by modulating brain inhibition, with potential for treating psychiatric disorders.
research Neurosteroid influence on affective tone
Endogenous neurosteroids may set a baseline mood.
research CURRENT PROSPECTIVE IN THE MANAGEMENT OF DEPRESSION USING OFF LABELLED DRUGS AND ADVANCED DRUGS
New medications are improving depression treatment, emphasizing accurate diagnosis and chronic care.
research Clobetasol/minoxidil
Community Join
5 / 1000+ resultscommunity DHT and 5AR respect post, it's importance within the brain
The conversation discusses whether to use finasteride for hair loss, considering its role in inhibiting DHT and 5AR, which can affect brain function and mood. Some users report anxiety and depression from finasteride, while others do not experience these side effects and emphasize the importance of DHT for brain and prostate health.
community concentration of my finasteride therapy
The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.
community CASSIOPEA ANNOUNCES VERY POSITIVE PHASE II TWELVE MONTHS RESULTS FOR BREEZULA® (CLASCOTERONE) IN TREATING ANDROGENETIC ALOPECIA
Clascoterone (Breezula) showed positive results for treating hair loss without affecting cortisol levels. Opinions vary, with some users optimistic about its potential and others critical of its effectiveness compared to existing treatments like finasteride.
community When will Breezula be released and how does it compare to KX-826?
Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.
community Brief update clascoterone phase 3 - Breezula
Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.